Login
Companies $TNGX
$24.22 +$0.05 (0.21%) After hours
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

tangotx.com

What Do They Do?

Develops targeted cancer medicines for patients selected by cancer-related genetic changes, including medicines for solid tumors and brain cancers.

How Do They Make Money?

Revenue has come mainly from Gilead license and collaboration agreements. Tango receives fees for licenses and research and development services; license fees may be paid upfront, while research fees are earned as the work progresses.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $101.6M in FY2025.

Operating income, FY2025
−178% of revenue
▲ +24% (Loss) vs FY2024 (−$145.6M, −346%)
Net income, FY2025
−163% of revenue
▲ +22% (Loss) vs FY2024 (−$130.3M, −310%)
Free cash flow, FY2025
−224% of revenue
▼ −6% (Loss) vs FY2024 (−$132.3M, −314%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $53.8M in Q3 FY2025
Net income
▼ Turned to a loss
vs $15.9M in Q3 FY2025
  • Nov 9, 2026 Tango plans a Phase 3 pancreatic cancer trial and reprioritized research toward PRMT5 therapies The company plans to start a vopimetostat-daraxonrasib trial in front-line MTAP-deleted pancreatic cancer in the first half of 2027.
  • Oct 23, 2026 Combination trial results prompted plans for a registrational pancreatic cancer study Vopimetostat plus daraxonrasib showed an 82% response rate and an 88% nine-month progression-free survival rate in second- and third-line pancreatic cancer patients.

Growing. Revenue grew 68% in 4 years, from $37M in FY2021 to $62.4M in FY2025, about 14% a year.

Who Do They Compete With?

Competes with AstraZeneca, Amgen, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Merck KGaA, Pfizer, Lilly, Roche, Artios Pharma, BeOne, Exelixis, IDEAYA Biosciences, Repare Therapeutics, Servier Pharmaceuticals, Abbisko, Insilico Medicine, and Jubilant Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support